Special Issue "Antisense Oligonucleotide Chemistry and Applications"
Deadline for manuscript submissions: closed (20 June 2019).
Interests: antisense oligonucleotides; aptamers; DNAzymes; antimiRs; chimeric nucleic acids; chemically-modified oligonucleotides
Synthetic antisense oligonucleotide (AO)-based therapy has attracted significant interests in the last decade, and offers enormous potential as therapeutics to various diseases. To date, five AO drugs have been approved by the US Food and Drug Administration (FDA) for clinical use including Vitravene for cytomegalovirus retinitis; Kynamro for familial hypercholesterolemia, Exondys51 for the treatment of Duchenne muscular dystrophy, Spinraza for the treatment of spinal muscular atrophy and very recently Tegsedi for Hereditary Transthyretin Amyloidosis. As you all know from these clinical translations that the use of chemically-modified nucleotide monomers in constructing AOs is absolutely essential in developing successful drugs.
This special issue covers various aspects of antisense oligonucleotide synthesis chemistries, and their applications in molecular medicine in the form of authentic research and review articles.
Dr. Rakesh N. Veedu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Antisense Oligonucleotides
- Antisense Therapy
- Chemically-modified Antisense Oligonucleotides
- Nucleic Acid Chemistry